ArticleArchives of microbiology2026
Zhuhuang Granules alleviate psoriatic inflammation via restoring gut microbiota balance and enhancing intestinal barrier integrity.
Article in Archives of microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Psoriasis is a chronic inflammatory skin disorder characterized by excessive keratinocyte proliferation, immune dysregulation, and systemic inflammation. Emerging evidences highlight the gut-skin axis as a key regulatory mechanism linking gut microbiota dysbiosis to psoriasis pathogenesis. This study investigates the therapeutic effects of Zhuhuang Granules (ZH) on psoriasis, focusing on cutaneous inflammation, intestinal barrier integrity, and gut microbiota homeostasis. Using an imiquimod (IMQ)-induced psoriasis-like dermatitis mouse model, ZH treatment significantly reduced Psoriasis Area and Severity Index (PASI) scores, epidermal hyperplasia, and inflammatory infiltration, with marked improvements observed following medium- and high-dose ZH treatment. ZH also suppressed systemic immune activation by decreasing spleen weight, inhibiting keratinocyte proliferation, and downregulating pro-inflammatory cytokines, including IL-22, IL-1β, TNF-α and CCL20. Additionally, ZH enhanced intestinal barrier function through the upregulation of essential tight junction proteins (TJP1, Occludin, and Claudin-1), leading to reduced intestinal permeability and systemic endotoxemia. 16S rRNA sequencing revealed that ZH partially reversed IMQ-induced gut dysbiosis, with partial restoration of several IMQ-associated microbial taxa, including Lachnospiraceae FCS020 group, Lachnospiraceae UCG-001, and Bacteroides. Functional prediction analysis indicated that ZH altered the predicted abundance of microbial functional pathways related to immune regulation and lipid metabolism. Importantly, antibiotic-mediated gut microbiota depletion attenuated the protective effects of ZH against IMQ-induced psoriasis-like inflammation, providing functional evidence for a contribution of the gut microbiota to the therapeutic effects of ZH. These findings suggest that ZH alleviates psoriasis-like inflammation through suppressing systemic inflammation, improved intestinal barrier functions, and microbiota restoration, supporting its therapeutic potential in psoriasis management.
Indexed as
Identifiers
42909639What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.